Neurological Sciences

, Volume 31, Supplement 3, pp 309–312

The cohort of the multiple sclerosis center of Cagliari

  • M. G. Marrosu
  • L. Lorefice
  • J. Frau
  • G. Coghe
  • G. Fenu
  • R. Piras
  • M. Melis
  • E. Cocco
Session II – Natalizumab: Italian Experience

Abstract

We report our experience in long-term treatment of relapsing remitting multiple sclerosis patients with natalizumab (N). In November 2009 we evaluated 141 patients (126 AIFA criterion A, 15 AIFA criterion B). We paid particular attention to the treatment period and the patients follow-up; during the whole therapeutic program, they undergone to clinical and radiological evaluation for every 3 months. The compliance was optimal and we found no significant side effects. 26 patients completed the 24 monthly doses. After 24 months 51% of patients were free from disease activity. We found a reduction in relapses and EDSS, moreover the clinical improvement was also confirmed by radiological examinations. Our results show that the best therapeutic results are achieved by early initiation of treatment.

Keywords

Multiple sclerosis Natalizumab Patient management 

References

  1. 1.
    Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of N for relapsing multiple sclerosis. N Engl J Med 354:899–910CrossRefPubMedGoogle Scholar
  2. 2.
    Rudick RA, Stuart WH, Calabresi PA et al (2006) N plus Interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923CrossRefPubMedGoogle Scholar
  3. 3.
    Dorsey ER, Thompson JP, Noyes K et al (2007) Quantifying the risks and benefits of N in relapsing multiple sclerosis. Neurology 68:1524–1528CrossRefPubMedGoogle Scholar
  4. 4.
    Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of N for relapsing multiple sclerosis. N Engl J Med 348:15–23CrossRefPubMedGoogle Scholar
  5. 5.
    Tedeschi G, Amato MP, D’Alessandro R et al (2009) The pharmacovigilance program on N in Italy: 2 years of experience. Neurol Sci 30(Suppl 2):S163–S165Google Scholar
  6. 6.
    Warnke C et al (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67(8):923–930CrossRefPubMedGoogle Scholar
  7. 7.
    Havrdova E, Galetta S, Stefoski D, Comi G (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Suppl 3):S3–S7Google Scholar
  8. 8.
    McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–176CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. G. Marrosu
    • 1
  • L. Lorefice
    • 1
  • J. Frau
    • 1
  • G. Coghe
    • 1
  • G. Fenu
    • 1
  • R. Piras
    • 1
  • M. Melis
    • 1
  • E. Cocco
    • 1
  1. 1.Centro Sclerosi Multipla, Dipartimento di Scienze Cardiovascolari e NeurologicheUniversità di CagliariCagliariItaly

Personalised recommendations